Mutation analysis of Pig-A gene in paroxysmal nocturnal hemoglobinuria

Paola Blanchi, Elisa Fermo, Carla Boschetti, Manuela Zappa, Cristina Vercellati, Fiorenza Barraco, Alberto Zanella

Research output: Contribution to journalArticle

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal stem cell disorder characterized by the expansion of an hemopoietic cell clone unable to produce the glycosyl-phosphatidyl inositol (GPI) anchor. A variety of mutations in the PIG-A gene has been so far detected in this disease. Although there is no specific treatment, recombinant human erythropoietin (rHu-EPO) has been reported to be effective in some cases. However, is not clear whether the possible beneficial effect of rHu-EPO is due to the stimulation of the normal or the GPI defective erythroid clone. The aim of this study was to investigate the molecular defect in 13 PNH patients, one of whom spontaneously recovered from the disease. Moreover, in one patient, the PIG-A negative clone was monitored by quantitative-competitive PCR during rHu-EPO treatment. The diagnosis of PNH was made by Ham's and sucrose hemolysis tests and by red cell CD55 and CD59 antigens determination. The study of the entire codifying region and flanking intronic sequences of PIG-A gene was done by SSCP analysis and sequencing. The DNA sequence revealed the presence of 9 new and one known mutations. In three patients no abnormalities were detected. We found 7 small deletions (del A231, del C243. del 258-264, del G342, del T689, del T774, del 1251-1254), one 7 nt duplication (dupl 604-610), and two missense mutations (T728C, new and C55T, already reported in PNH). This latter was found in the spontaneously recovered patient and in another case in combination with T728C. C55T was also detected in the mucous membrane cells and in one out of 50 normal controls, thus confirming its polymorphic nature. Whether it may represent a predisposing factor for PNH remains to be elucidated. Moreover, in one patient (del T689) undergoing rHu-EPO treatment, a specific primer for the mutation was prepared and used for quantitative-competitive PCR. The increase in hemoglobin levels (from 7.3 to 9 g/dL) was related with an increase of PIG-A negative molecules (from 102 to 5x 10' in 100 ng DNA) and of CD55'/CD59 cells (from 53 to 98%), suggesting that in this patient the efficacy of rHu-EPO therapy was connected with the stimulation of the abnormal clone.

Original languageEnglish
JournalBlood
Volume96
Issue number11 PART II
Publication statusPublished - 2000

Fingerprint

Paroxysmal Hemoglobinuria
Erythropoietin
Swine
Genes
Mutation
Clone Cells
Phosphatidylinositols
Clone cells
CD59 Antigens
CD55 Antigens
DNA sequences
Single-Stranded Conformational Polymorphism
Polymerase Chain Reaction
Stem cells
Anchors
Missense Mutation
Sucrose
Therapeutics
Hemolysis
Hemoglobins

ASJC Scopus subject areas

  • Hematology

Cite this

Blanchi, P., Fermo, E., Boschetti, C., Zappa, M., Vercellati, C., Barraco, F., & Zanella, A. (2000). Mutation analysis of Pig-A gene in paroxysmal nocturnal hemoglobinuria. Blood, 96(11 PART II).

Mutation analysis of Pig-A gene in paroxysmal nocturnal hemoglobinuria. / Blanchi, Paola; Fermo, Elisa; Boschetti, Carla; Zappa, Manuela; Vercellati, Cristina; Barraco, Fiorenza; Zanella, Alberto.

In: Blood, Vol. 96, No. 11 PART II, 2000.

Research output: Contribution to journalArticle

Blanchi, P, Fermo, E, Boschetti, C, Zappa, M, Vercellati, C, Barraco, F & Zanella, A 2000, 'Mutation analysis of Pig-A gene in paroxysmal nocturnal hemoglobinuria', Blood, vol. 96, no. 11 PART II.
Blanchi, Paola ; Fermo, Elisa ; Boschetti, Carla ; Zappa, Manuela ; Vercellati, Cristina ; Barraco, Fiorenza ; Zanella, Alberto. / Mutation analysis of Pig-A gene in paroxysmal nocturnal hemoglobinuria. In: Blood. 2000 ; Vol. 96, No. 11 PART II.
@article{7373d9112d1042a1ba388e0f73c65b1a,
title = "Mutation analysis of Pig-A gene in paroxysmal nocturnal hemoglobinuria",
abstract = "Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal stem cell disorder characterized by the expansion of an hemopoietic cell clone unable to produce the glycosyl-phosphatidyl inositol (GPI) anchor. A variety of mutations in the PIG-A gene has been so far detected in this disease. Although there is no specific treatment, recombinant human erythropoietin (rHu-EPO) has been reported to be effective in some cases. However, is not clear whether the possible beneficial effect of rHu-EPO is due to the stimulation of the normal or the GPI defective erythroid clone. The aim of this study was to investigate the molecular defect in 13 PNH patients, one of whom spontaneously recovered from the disease. Moreover, in one patient, the PIG-A negative clone was monitored by quantitative-competitive PCR during rHu-EPO treatment. The diagnosis of PNH was made by Ham's and sucrose hemolysis tests and by red cell CD55 and CD59 antigens determination. The study of the entire codifying region and flanking intronic sequences of PIG-A gene was done by SSCP analysis and sequencing. The DNA sequence revealed the presence of 9 new and one known mutations. In three patients no abnormalities were detected. We found 7 small deletions (del A231, del C243. del 258-264, del G342, del T689, del T774, del 1251-1254), one 7 nt duplication (dupl 604-610), and two missense mutations (T728C, new and C55T, already reported in PNH). This latter was found in the spontaneously recovered patient and in another case in combination with T728C. C55T was also detected in the mucous membrane cells and in one out of 50 normal controls, thus confirming its polymorphic nature. Whether it may represent a predisposing factor for PNH remains to be elucidated. Moreover, in one patient (del T689) undergoing rHu-EPO treatment, a specific primer for the mutation was prepared and used for quantitative-competitive PCR. The increase in hemoglobin levels (from 7.3 to 9 g/dL) was related with an increase of PIG-A negative molecules (from 102 to 5x 10' in 100 ng DNA) and of CD55'/CD59 cells (from 53 to 98{\%}), suggesting that in this patient the efficacy of rHu-EPO therapy was connected with the stimulation of the abnormal clone.",
author = "Paola Blanchi and Elisa Fermo and Carla Boschetti and Manuela Zappa and Cristina Vercellati and Fiorenza Barraco and Alberto Zanella",
year = "2000",
language = "English",
volume = "96",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11 PART II",

}

TY - JOUR

T1 - Mutation analysis of Pig-A gene in paroxysmal nocturnal hemoglobinuria

AU - Blanchi, Paola

AU - Fermo, Elisa

AU - Boschetti, Carla

AU - Zappa, Manuela

AU - Vercellati, Cristina

AU - Barraco, Fiorenza

AU - Zanella, Alberto

PY - 2000

Y1 - 2000

N2 - Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal stem cell disorder characterized by the expansion of an hemopoietic cell clone unable to produce the glycosyl-phosphatidyl inositol (GPI) anchor. A variety of mutations in the PIG-A gene has been so far detected in this disease. Although there is no specific treatment, recombinant human erythropoietin (rHu-EPO) has been reported to be effective in some cases. However, is not clear whether the possible beneficial effect of rHu-EPO is due to the stimulation of the normal or the GPI defective erythroid clone. The aim of this study was to investigate the molecular defect in 13 PNH patients, one of whom spontaneously recovered from the disease. Moreover, in one patient, the PIG-A negative clone was monitored by quantitative-competitive PCR during rHu-EPO treatment. The diagnosis of PNH was made by Ham's and sucrose hemolysis tests and by red cell CD55 and CD59 antigens determination. The study of the entire codifying region and flanking intronic sequences of PIG-A gene was done by SSCP analysis and sequencing. The DNA sequence revealed the presence of 9 new and one known mutations. In three patients no abnormalities were detected. We found 7 small deletions (del A231, del C243. del 258-264, del G342, del T689, del T774, del 1251-1254), one 7 nt duplication (dupl 604-610), and two missense mutations (T728C, new and C55T, already reported in PNH). This latter was found in the spontaneously recovered patient and in another case in combination with T728C. C55T was also detected in the mucous membrane cells and in one out of 50 normal controls, thus confirming its polymorphic nature. Whether it may represent a predisposing factor for PNH remains to be elucidated. Moreover, in one patient (del T689) undergoing rHu-EPO treatment, a specific primer for the mutation was prepared and used for quantitative-competitive PCR. The increase in hemoglobin levels (from 7.3 to 9 g/dL) was related with an increase of PIG-A negative molecules (from 102 to 5x 10' in 100 ng DNA) and of CD55'/CD59 cells (from 53 to 98%), suggesting that in this patient the efficacy of rHu-EPO therapy was connected with the stimulation of the abnormal clone.

AB - Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal stem cell disorder characterized by the expansion of an hemopoietic cell clone unable to produce the glycosyl-phosphatidyl inositol (GPI) anchor. A variety of mutations in the PIG-A gene has been so far detected in this disease. Although there is no specific treatment, recombinant human erythropoietin (rHu-EPO) has been reported to be effective in some cases. However, is not clear whether the possible beneficial effect of rHu-EPO is due to the stimulation of the normal or the GPI defective erythroid clone. The aim of this study was to investigate the molecular defect in 13 PNH patients, one of whom spontaneously recovered from the disease. Moreover, in one patient, the PIG-A negative clone was monitored by quantitative-competitive PCR during rHu-EPO treatment. The diagnosis of PNH was made by Ham's and sucrose hemolysis tests and by red cell CD55 and CD59 antigens determination. The study of the entire codifying region and flanking intronic sequences of PIG-A gene was done by SSCP analysis and sequencing. The DNA sequence revealed the presence of 9 new and one known mutations. In three patients no abnormalities were detected. We found 7 small deletions (del A231, del C243. del 258-264, del G342, del T689, del T774, del 1251-1254), one 7 nt duplication (dupl 604-610), and two missense mutations (T728C, new and C55T, already reported in PNH). This latter was found in the spontaneously recovered patient and in another case in combination with T728C. C55T was also detected in the mucous membrane cells and in one out of 50 normal controls, thus confirming its polymorphic nature. Whether it may represent a predisposing factor for PNH remains to be elucidated. Moreover, in one patient (del T689) undergoing rHu-EPO treatment, a specific primer for the mutation was prepared and used for quantitative-competitive PCR. The increase in hemoglobin levels (from 7.3 to 9 g/dL) was related with an increase of PIG-A negative molecules (from 102 to 5x 10' in 100 ng DNA) and of CD55'/CD59 cells (from 53 to 98%), suggesting that in this patient the efficacy of rHu-EPO therapy was connected with the stimulation of the abnormal clone.

UR - http://www.scopus.com/inward/record.url?scp=33748554903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748554903&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748554903

VL - 96

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11 PART II

ER -